Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets Hard-to-Treat cancers with MET gene change

NCT ID NCT07196644

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 6 times

Summary

This phase 2 study tests an investigational drug called telisotuzumab adizutecan in about 100 people aged 12 and older with advanced solid tumors that have a specific genetic change (MET amplification). The drug is given through an IV and aims to shrink tumors or stop them from growing. Researchers will monitor side effects and how well the drug works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
telisotuzumab adizutecan
What this could lead to
If successful, this could provide a new treatment option for people with advanced cancers that have a specific genetic change (MET amplification).
What could go wrong
This is an early-phase trial with only 100 participants, so results may not apply to everyone. The drug may cause side effects or not shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Locally advanced/metastatic solid tumors with documented MET amplification via Local next generation sequencing (NGS) or Central NGS via FoundationOne Companion Diagnostic (F1CDx). * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 * Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-Oncology (RANO) 2.0 criteria as appropriate to tumor type. * Received prior systemic therapy appropriate for their tumor type and stage of disease and who have no satisfactory alternative therapy for advanced solid tumors that would be expected to provide a substantial survival benefit for their tumor type. * If participant has central nervous system (CNS) metastasis, these should be clinically asymptomatic or radiologically stable (i.e., without evidence of progression after definitive treatment). Exclusion Criteria: * Current, historical, or suspected (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids. * Any major, life-threatening conditions and life expectancy should be at least 12 weeks.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumors harboring MET amplification

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    38 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beverly Hills Cancer Center /ID# 275465

    RECRUITING

    Beverly Hills, California, 90211, United States

  • City of Hope National Medical Center /ID# 275613

    RECRUITING

    Duarte, California, 91010, United States

  • Clinica Universidad de Navarra - Pamplona /ID# 275503

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Dell Seton Medical Center /ID# 276474

    RECRUITING

    Austin, Texas, 78701, United States

  • Duke Cancer Institute /ID# 275604

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Florida Cancer Specialists - North /ID# 277137

    RECRUITING

    St. Petersburg, Florida, 33705, United States

  • Hadassah Medical Center-Hebrew University /ID# 274343

    RECRUITING

    Jerusalem, 91120, Israel

  • Hokkaido University Hospital /ID# 276333

    RECRUITING

    Sapporo, Hokkaido, 060-8648, Japan

  • Hospital Clinico Universitario de Valencia /ID# 275501

    RECRUITING

    Valencia, 46010, Spain

  • Hospital General Universitario Gregorio Maranon /ID# 275498

    RECRUITING

    Madrid, 28007, Spain

  • Hospital Universitario 12 de Octubre /ID# 275496

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario Vall de Hebron /ID# 275499

    RECRUITING

    Barcelona, 08035, Spain

  • Kyoto University Hospital /ID# 276398

    RECRUITING

    Kyoto, Kyoto, 606-8507, Japan

  • Kyushu University Hospital /ID# 276302

    RECRUITING

    Fukuoka, Fukuoka, 812-8582, Japan

  • Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 275999

    RECRUITING

    New York, New York, 10065, United States

  • Nagoya University Hospital /ID# 276336

    RECRUITING

    Nagoya, Aichi-ken, 466-8560, Japan

  • National Cancer Center Hospital /ID# 276297

    RECRUITING

    Chuo-Ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East /ID# 276298

    RECRUITING

    Kashiwa-shi, Chiba, 277-8577, Japan

  • Northwestern University Feinberg School of Medicine /ID# 276436

    RECRUITING

    Chicago, Illinois, 60611-2927, United States

  • Okayama University Hospital /ID# 276299

    RECRUITING

    Okayama, Okayama-ken, 700-8558, Japan

  • Rabin Medical Center. /ID# 274341

    RECRUITING

    Petah Tikva, Central District, 4941492, Israel

  • SCRI Oncology Partners /ID# 275686

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • START Midwest /ID# 276603

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • Samsung Medical Center /ID# 275705

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • Seoul National University Hospital /ID# 275703

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • South Texas Accelerated Research Therapeutics /ID# 276608

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Stanford University - Palo Alto /ID# 282083

    RECRUITING

    Palo Alto, California, 94304, United States

  • Start Mountain Region /ID# 276607

    RECRUITING

    West Valley City, Utah, 84119, United States

  • Tel Aviv Sourasky Medical Center /ID# 274344

    RECRUITING

    Tel Aviv, Tel Aviv, 6423906, Israel

  • The Chaim Sheba Medical Center /ID# 274342

    RECRUITING

    Ramat Gan, Tel Aviv, 5265601, Israel

  • The University of Texas MD Anderson Cancer Center /ID# 275663

    RECRUITING

    Houston, Texas, 77030, United States

  • Tohoku University Hospital /ID# 276344

    RECRUITING

    Sendai, Miyagi, 980-8574, Japan

  • University of Chicago Medical Center /ID# 275342

    RECRUITING

    Chicago, Illinois, 60637, United States

  • University of Texas - Southwestern Medical Center /ID# 276053

    RECRUITING

    Dallas, Texas, 75235, United States

  • Valkyrie Clinical Trials /ID# 275547

    RECRUITING

    Los Angeles, California, 90067, United States

  • Virginia Cancer Specialists - Fairfax /ID# 276010

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Yale University School of Medicine /ID# 275978

    RECRUITING

    New Haven, Connecticut, 06510, United States

  • Yonsei University Health System Severance Hospital /ID# 276184

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.